Introduction
After many years of development, monoclonal antibody (mAb)-based therapies have become a critical part of the treatment of patients with autoimmunity, cancer and infectious disease. These therapeutic antibodies all work by exploiting their ability seek out and selectively bind to their target molecules in the patient. Current approved therapeutic antibody products are targeted directly to pathogens, cancer cells or molecules that contribute to disease. Antibody-targeted vaccines (ATVs), exploit the same targeting properties of antibodies, but are directed to normal cells of the immune system. In the case of ATVs, antibodies are used to deliver a cargo of antigens to professional antigen-presenting cells (APCs) with the goal of inducing or enhancing immunity to the antigen. Although APCs have passive mechanisms for internalizing antigens for processing and subsequent presentation, they are relatively rare cells in the body and this process can be made far more efficient by targeting antigens to cell surface receptors on APCs. Moreover, antibodies specific for endocytic receptors on APCs can lead to antigen accumulation in the intracellular vesicles that are critical for loading appropriate major histocompatibility complex (MHC) molecules required for eliciting effector T-cell responses.
Professional APCs are critical for the induction of potent antigen-specific immune responses. Among APCs, dendritic cells (DCs) are particularly specialized for inducing potent immune responses owing to their high expression of cell surface receptors and a number of complementary molecules that participate in interactions with T lymphocytes (Mellman and Steinman, 2001) . DCs also secrete many immune modulators such as cytokines and chemokines to initiate an immune response, which results in the amplification of both cellular and humoral immunity. DCs express on their surface high levels of MHC molecules that bind and display fragments of antigens for recognition by T cells with the appropriate T-cell receptors. Antigens taken up by DCs can be processed and presented by both MHC class I and II molecules to specific CD8 þ and CD4 þ T cells, respectively, with the former involving a process called cross-presentation or cross-priming (Bevan, 1976; Rock, 1996; Melief, 2003) . This process is critical for induction of cytolytic T-cell (CTL) responses, which are important for effective antiviral and antitumor immunity. The first studies of highly efficient processing and presentation of antigens targeted to APC-surface molecules were published over 20 years ago. B cells were shown to be very efficient at selectively presenting their specific antigen or antibodies targeted to their cell surface antigen receptors (Chesnut and Grey, 1981; Tony and Parker, 1985) . Since that time, a number of other APC cell surface molecules have been used for targeted antigen-delivery experiments, and there has also been a tremendous effort in the field of antibody engineering and development, which has led to relatively straightforward approaches to generating a variety of antibody-based vectors. Fusion proteins between antibodies and antigens can now be readily constructed by molecular engineering (Figure 1 ), and these products can be expressed in well-developed manufacturing processes that can simplify the translation to clinical studies, and provide a viable product development opportunity. The ability to generate targeting antibodies with human sequences, primarily via various applications of genetic engineering technologies, further enhances the applicability of ATVs for human use.
The first efforts at using antibodies to develop vaccination approaches based on the delivery of antigens to APCs, focused on the induction of humoral responses. Using model antigens targeted to MHC molecules and Fc receptors, without adjuvant, led to antigen-specific antibody titers that were comparable to immunizations with antigen emulsified in complete Freund's adjuvant (CFA) Barber, 1987, 1990; Segal, 1987, 1989; Carayanniotis et al., 1988 Carayanniotis et al., , 1991 Snider et al., 1990) . These seminal studies also demonstrated that robust antibody responses to ATVs could be generated at very low antigen concentrations. In subsequent studies, targeting antigen to CD11c, which is expressed predominantly on DCs in the mouse, resulted in IgG responses that were measurable 5 days after a single immunization without adjuvant, and splenocytes from immunized mice could be successfully fused to create IgG-secreting hybridomas only 10 days after a single immunization (Wang et al., 2000; Berry et al., 2003) . ATVs have also been exploited for induction of helper and CTL responses.
A variety of receptors have been exploited for enhancing immune responses using ATVs, with expression profiles that range from relatively APC specific to more widespread patterns (Keler et al., 2005; Tacken et al., 2006) . Successfully targeted receptors include family members of the integrins, immunoglobulin superfamily, TNF receptors, complement receptors, and C-type lectin receptors (CLRs). As much of the recent effort has focused on targeting to CLRs, this review will highlight these approaches to vaccine development.
Targeting antigens to CLRs
CLRs are pattern recognition receptors that are abundantly expressed on various APCs populations (Figure 2 ; Gordon, 2002; Pyz et al., 2006) . A characteristic feature shared by many CLRs is their endocytic capacity and the presence of carbohydrate recognition domains (CRDs). The CRDs can selectively bind to glycans associated with microorganisms and lead to rapid internalization (Ezekowitz et al., 1991; Brown et al., 2003; Mansour et al., 2006) . This process can initiate effective immune defense, although some pathogens may subvert this pathway and suppress beneficial immune responses (Turville et al., 2003; van Kooyk et al., 2004) . Some CLRs that contain a specific triad of acidic amino acids in their carboxyl terminus (e.g. DEC-205) traffic directly to late endosomes that are rich in MHC class II molecules, other CLRs (e.g. mannose receptor (MR)) possess tyrosine-based motifs and rapidly recycle via early endosomes . This diversity in the intracellular routing may have significant impact on the processing and presentation of antigens. . These ligands can be found on both pathogens and host-derived molecules (Allavena et al., 2004) . In addition to the expression of MR on macrophages where it was initially identified, MR expression has been demonstrated on immature DCs, subsets of endothelial cells and some other cell types (Stahl, 1992; Uccini et al., 1997) . Among DC populations, MR expression is abundant on mouse bone marrow-derived DC, human monocyte-derived DCs and interstitial DCs, such as dermal DCs (Sallusto et al., 1995; Uccini et al., 1997) . MR is not expressed by Langerhans cells in the epidermis or by plasmacytoid DCs (Mommaas et al., 1999; Guo et al., 2000) . Interestingly, MR-expressing DCs are found in the epidermis of patients with active dermatitis, suggesting that these MR-expressing APCs may be mobilized to inflammatory sites (Wollenberg et al., 2002) , or MR expression may be induced locally by inflammatory mediators. Either way they may be involved in the endocytosis and clearance of microorganisms and serum glycoproteins, as well as locally presenting antigens derived from these entities. Although an endocytic receptor, MR alone is not able to initiate phagocytosis (Le Cabec et al., 2005) and consequently plays an important role in uptake and presentation of soluble, but not cell-associated antigens (Burgdorf et al., 2006) .
Ligands containing mannan or mannose have been successfully used in various forms to direct antigens to APCs, thus generating more efficient immune responses (Tan et al., 1997; Agnes et al., 1998; Apostolopoulos et al., 2000; Keler et al., 2004) . The use of MR ligands for targeting APCs has been widely applied for enhancing antigen-specific immunity, but these ligands are not specific for MR, thus the contribution of MR relative to other mannan-binding receptors, such as DC-specific intracellular adhesion molecule (ICAM)-grabbing non-integrin (DC-SIGN), to the enhanced immune responses remains to be established. The use of CLR-specific antibodies is now permitting the investigation of immune responses mediated by the individual receptors.
Studies by our laboratory have demonstrated that targeting of tumor antigens to the MR on monocytederived DCs using a human MR-specific mAb can efficiently sensitize antigen-specific T cells which display MHC class I-and class II-restricted activity (He et al., 2004; Ramakrishna et al., 2004) . Importantly, the MRtargeted vaccines elicited CTL responses to multiple epitopes, which resulted in specific lysis of histocompatibility leukocyte antigen-matched tumor cells naturally expressing the antigen. Results obtained using confocal microscopy demonstrated that the internalized anti-MR mAb localized to MHC class I-containing vesicles, but not to MHC class II-containing vesicles, both in peripheral and in internal vesicular compartments.
Using a transgenic mouse model in which the human MR is expressed under the control of its own promoter, MR-targeted ATVs have demonstrated efficient targeting to MR-expressing cells in vivo. Moreover, these ATVs were only effective in potent immune responses and antitumor activity in the MR-tg mice. Strong cellular immunity was dependent on concomitant administration of adjuvants (He et al., 2006) .
Clinical development of ATVs has in fact been initiated with a fusion protein (CDX-1307) composed of an MR-specific IgG1k human mAb (clone B11) and the beta (b) chain of human chorionic gonadotropin (hCG). hCG-b is overexpressed in a variety of common cancers including those of the colon, lung, pancreas, esophagus, breast, bladder, cervix, stomach and prostate (Triozzi and Stevens, 1999; Butler and Iles, 2003) . Elevated hCG-b serum levels and/or tissue expression have been shown to be independent predictors of disease outcome and are associated with a more aggressive disease course in renal, colorectal, bladder and pancreatic cancers. To our knowledge, this is the first investigation of ATVs in human clinical trials. CDX-1307 is currently in two dose escalation phase I clinical trials for patients with incurable cancers. The primary distinction between the studies is the route of administration, which includes intradermal and intravenous to compare the local versus systemic vaccine effects.
DEC-205
DEC-205 is a CLR belonging to the MR family (Kato et al., 2006) . DEC-205 contains 10 CRDs for which the specific ligands remain to be identified. The human and murine DEC-205 share 77% identity, and their expression is primarily restricted to DCs and thymic cortical epithelium, although human DEC-205 can also be detected on peripheral T and B cells (Kato et al., 2006) . A distinguishing feature of DEC-205 is its highlevel expression on DCs in the T-cell areas of lymphoid organs, suggesting a role in regulating T-cell responses. DEC-205 is internalized by means of coated pits and vesicles, and traffics to endosomal compartments that are rich in MHC class II molecules (Jiang et al., 1995) . In contrast, MR expression on DCs is primarily restricted to interstitial DCs such as dermal DCs, and traffics to early endosomes that do not contain MHC class II .
The potential of antigen targeting to DEC-205 has been pioneered by Drs Steinman and Nussenzweig at Rockefeller University. Initial studies demonstrated the ability of rabbit antibodies specific for mouse DEC-205 to be presented to reactive T-cell hybridomas 100-fold more efficiently than irrelevant rabbit IgG (Jiang et al., 1995) . Further studies showed that the DEC-205 cytosolic domain drives a receptor-mediated endocytosis that involves efficient recycling through late endosomes . In addition, compared to the MR cytosolic domain, the intracellular routing by DEC-205 was more efficient in presenting antigen to CD4 þ T cells. Priming antigen-specific CD4 T cells with ATVs specific for the DEC-205 receptor on DCs in vivo resulted in remarkable expansion of antigen specific, MHC class II restricted T cells (Hawiger et al., 2001) . These studies demonstrated that targeting to DEC-205 was far more efficient for induction of T-cell responses than immunogenic peptide mixed with CFA. However, to maintain the T-cell response and prevent antigen-specific anergy, activation signals provided by an agonistic anti-CD40 mAb were required.
Recently, the use of ATVs to elicit protective and therapeutic immunity has been addressed using tumor cells or pathogens that were modified to express ovalbumin (OVA) as a model antigen (Bonifaz et al., 2004b) . Targeting OVA to DEC-205 in mice resulted in exceptional cross-presentation of antigen to CTL (Bonifaz et al., 2002) . Similar to the effect observed on CD4 T cells, induction of sustained immunity required co-administration of activating signals in the form of anti-CD40 mAbs or CFA (Bonifaz et al., 2002 (Bonifaz et al., , 2004b . Similar data has also been obtained with DEC-205 targeted survivin (Charalambous et al., 2006) and human immunodeficiency virus antigens (Trumpfheller et al., 2006) . Bonifaz et al. (2004b) also demonstrated the induction of substantial antitumor effects when mice were challenged with OVA expressing syngeneic tumor cells. The protection in this model required CD8 T cells and demonstrated that cross-presentation in vivo was essential for the protective responses. Despite the use of local immunization, the targeted vaccine resulted in systemic antigen loading of DCs and MHC class I presentation that persisted for at least 2 weeks. Furthermore, administration of this ATV 1 week posttumor challenge resulted in a more significant delay of tumor progression compared to other popular methods of vaccinating. Mahnke et al. (2005) developed DEC-205 targeted ATVs with the melanoma antigen tyrosinase-related protein-2 and used a vaccination strategy combined with cytosine-guanosine oligonucleotide (CpG) oligodeoxynucleotides to investigate the effect on tumor challenge with the melanoma cell line B16. The DEC-205-targeted vaccination protected mice against tumor growth and substantially slowed the growth of previously implanted B16 cells. Protection was mediated by melanomaspecific CD4 and CD8 T-cell responses.
A DEC-205-targeted ATV was also investigated in a model of viral infection (Bonifaz et al., 2004a) . Subcutaneously delivered DEC-205-targeted OVA in combination with the agonist anti-CD40 mAb induced immunity against infection with OVA modified vaccinia virus administered intranasally. Mice vaccinated with the ATV had significantly reduced virus titers and symptoms compared to controls.
In most of the systems studied thus far, induction of antigen-specific immunity with DEC-205-targeted ATVs was dependent on concomitant delivery of a DC activation/maturation signal. In fact, antigens targeted to DEC-205, in the absence of activating stimuli, can induce profound peripheral T-cell tolerance (Hawiger et al., 2001; Bonifaz et al., 2002) . These findings are consistent with the concept that DCs play a critical role in maintaining tolerance to self-antigens in the absence of DC activation signals (Heath and Carbone, 2001 ). Thus, in the absence of DC activation, APC targeting may also be exploited therapeutically to develop specific immunosuppressive ATVs that have useful application for treatment of autoimmune diseases, transplantation or allergy. This is discussed briefly at the end of this review.
DC-SIGN DC-specific ICAM-grabbing non-integrin (DC-SIGN)
is the founding member of a family of type II membrane-spanning CLRs that is expressed by DCs and macrophages (Geijtenbeek et al., 2000) . It has been most actively investigated for its role in binding and promoting human immunodeficiency virus infection of T cells (Geijtenbeek et al., 2000; Bashirova et al., 2001; Pohlmann et al., 2001) , but also has a number of other ligands, including interactions with ebola, measles and herpes viruses and Neisseria gonorrhoeae and meningitides. In addition, DC-SIGN is important in the interaction between DCs and T cells through its ICAM-3 binding function. The expression of DC-SIGN is particularly well suited to ATV approaches as the receptor is expressed at high levels by multiple DC populations that can contribute to T-cell priming and activation. Similar to MR, DC-SIGN is an endocytic receptor that can mediate efficient antigen presentation through different ligands, and more recently using a novel humanized antibody, hD1 (Schjetne et al., 2002; Tacken et al., 2005; Dakappagari et al., 2006) .
Studies by Tacken et al. (2005) used keyhole limpet hemocyanin (KLH)-conjugated to hD1 to investigate internalization, trafficking and presentation of KLH. The DC-SIGN targeted ATV was rapidly internalized and subsequently routed to the lysosomal compartments. DCs pulsed with the ATV enhanced the proliferation of autologous peripheral blood lymphocytes (PBLs) from KLH vaccinated patients at a 100-fold lower concentration than KLH-pulsed DCs. The hD1-KLH ATV also elicited KLH-specific T cells from unvaccinated donors, and blocking antibodies to MHC molecules suggested that the ATV induced proliferation of T cells recognizing KLH epitopes in the context both MHC class I and MHC class II. Consistent with the previous studies using MR and DEC-205, these studies were also performed in the context of the strong DC activation and maturation stimuli, lipopolysaccharide. Whether or not targeting DC-SIGN will trigger tolerance in the absence of DC-activating agents is currently not known.
Other CLRs
Different APCs express a number of other CLRs that are also beginning to be explored for their utility in APC-targeted antigen delivery (e.g. Dectin-1, Dectin-2, BDCA-2, DCIR, DCAR, Langerin and MGL). With emerging data on signaling activities of these different molecules, either direct or via their interactions with other activating receptors (e.g. Toll-like receptors (TLR) or Fc receptors), it is likely that some could offer different opportunities for therapeutic applications. Two examples will be discussed briefly in this section.
Dectin-1 DC-associated C-type lectin-1 (Dectin-1) is an NK cell receptor-like molecule expressed by APCs and some
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other myeloid cells that lacks CRDs but acts as a major receptor for b-glucans, and thus recognizes and can endocytose a number of fungal species, including yeast and Aspergillus (Ariizumi et al., 2000; Brown, 2006) . Unlike other CLRs, Dectin-1 has an activating ITAM motif in its cytoplasmic tail, and cross-linking this receptor leads to APC activation and pro inflammatory mediator production (Gantner et al., 2003; Brown, 2006) , as well as synergistic interaction with other innate signaling molecules such as TLR2 (Gantner et al., 2003) . Dectin-1 can also signal to regulate innate immune responses through activation of the Syk tyrosine kinase and subsequent production of interleukin (IL)-2 and IL-10 ( Rogers et al., 2005) . In the mouse, Dectin-1 is expressed by CD8a
þ DCs in spleen, lymph nodes and in skin (dermal DCs) and a recent study by Carter et al. (2006b) has shown efficient induction of both T cell (CD4 and CD8) and antibody responses by antigen delivered with a Dectin-1-targeting antibody. They also compared responses to Dectin-targeted antigen with those triggered with a DEC-205-targeting antibody, that targets CD8a þ CD11b À DCs and found qualitatively different outcomes. Dectin-1 produced stronger antibody and CD4 T cell responses, whereas DEC-205 was much better at stimulating CD8 T-cells. This data supports the concept of different applications for different targeting molecules, although it is also possible that the differences are due to inherent differences between the two antibody-antigen conjugates used (e.g. relative affinity). As evidenced by studies of different antibodies to MR, different receptor epitopes can also trigger quite different responses (Chieppa et al., 2003) .
Dectin-2
Dectin-2 is a myeloid-lineage restricted cation-dependent carbohydrate-binding receptor that can recognize fungal hyphae and has a particular selectivity for high mannose structures (McGreal et al., 2006) . Its expression is upregulated in macrophage lineage cells under activating inflammatory conditions (Sato et al., 2006) , and although it appears to lack any cytoplasmic signaling domains it can couple with FcRg to trigger innate immune responses. Unlike Dectin-1-targeting data discussed above, anti-Dectin-2-coupled antigen has been shown to efficiently induce CD8 T-cell responses (Carter et al., 2006a) .
Immunosuppressive ATVs for autoimmune and allergic disorders
The immune response to antigen is a tightly regulated process that, under normal physiological conditions, serves to protect against pathogens while minimizing effects on self tissues. However, autoimmune diseases and allergies can develop when failure of control mechanisms leads to chronic and excessive immune activation. Autoimmune diseases such as multiple sclerosis and type I diabetes, result from inappropriate (often Th1-biased) immune responses to self-tissues, whereas allergic disorders are due to uncontrolled Th2-biased responses to exogenous antigens.
Most current treatments for autoimmune and allergic disorders are largely directed at providing symptomatic relief and do not tackle the underlying mechanisms driving these chronic pathologies. Ideally, treatments should be targeted selectively to modulate the antigen responses specifically driving disease pathology, as these should be most effective and could be able to reestablish appropriate control mechanisms (e.g. regulatory T cells) to provide long-term disease modification (Larche and Wraith, 2005) . The successes achieved over the past few years in the treatment of certain allergies using different allergen-based immunotherapeutics has provided proof of concept that long-term antigenspecific disease modification is achievable, and mechanistic studies have indicated that successful therapy does indeed involve amplification of regulatory mechanisms (Larche et al., 2006) . However, these treatments are still mainly individually tailored and involve many visits to specialist clinics over a number of years -so there is clearly a desire for improved products in this arena as well as for products that take a similar approach for autoimmune disease treatments, albeit targeting different immune mechanisms. Finkelman et al. (1996) were the first to demonstrate immune tolerance induction via antibodies targeting DCs. They showed that mice treated with the rat IgG2b anti-DC antibody 33D1 developed both T-and B-cell hyporesponsiveness to subsequent challenge with rat IgG2b antigen. In these same studies, a different DCspecific antibody (the hamster anti-CD11c antibody N418) stimulated antibody responses rather than inducing tolerance, suggesting that DC surface molecules may differ in their tolerogenic potential. A number of different APC-targeting approaches have since been explored for their potential at triggering or reinforcing immune tolerance mechanisms as a basis for immunotherapeutics. This is particularly well exemplified by the studies of Steinman and co-workers referred to earlier, where antigen targeting to DC surface DEC-205 in vivo in the absence of DC maturation signals induced active and specific immune tolerance to the antigen (Steinman et al., 2003) . These studies with model antigens have since been followed up in models of autoimmune diseases. Hawiger et al. (2001) used a spontaneous onset transgenic model of type I diabetes, whereas Bruder et al. (2005) used an experimentally induced acute encephalitis system (EAE), a model of some features of multiple sclerosis. In both settings, treating with a DEC-205-targeted version of the relevant antigen (in the absence of adjuvant) before disease onset or induction induced a marked suppression of disease symptoms and pathology. Mechanistically, active immune suppression involving the amplification of regulatory T-cell function is thought to be involved in controlling pathologic effector responses (Steinman et al., 2003; Maksimow et al., 2006) . Whether or not such strategies will be capable of re-inducing tolerance of pre-primed immunity or of suppressing ongoing pathogenic effector responses, which will be required for the development of successful therapeutic approaches, remains to be determined. Clearly, with respect to the use of ATVs in therapy of cancer or infectious diseases inadvertant induction of immune suppression needs to be avoided through the use of suitable DC-activating agents (Steinman et al., 2003; Maksimow et al., 2006) .
Whether or not other APC surface molecules can also be targeted for the induction of immune tolerance is currently unclear. Alveolar macrophages express MR which has been shown to be involved in suppressing local inflammatory responses (Zhang et al., 2005) and cross linking of MR on DCs by certain antibodies has been shown to elicit an anti-inflammatory, immunosuppressive program of cytokine secretion, including high IL-10 and suppressed IL-12 (Chieppa et al., 2003) . Such immunosuppressive responses may have direct relevance to allergic responses in the airways, since the DC binding and uptake of the major dust-mite allergen Der p1 has been shown to involve MR (Deslee et al., 2002) . Recent studies with the macrophage galactose-type Ctype lectin (MGL), which is another endocytic receptor also expressed by DCs, have shown that this molecule has suppressive interactions with T cells through its binding to CD45 (van Vliet et al., 2006) , and another CLR, DCAL-2, has also been shown to have immunoregulatory properties . In addition to peripheral immune suppression, APC-targeting may also be able to induce central (thymus) T-cell tolerance to peptide antigens (Schjetne et al., 2005) . Finally, recent disease model studies have explored the potential of using Fc receptor targeting to deliver immunomodulatory approaches for the treatment of rheumatoid arthritis (van Vuuren et al., 2006; Wenink et al., 2006) .
Further studies of immunosuppressive APC-targeting approaches will no doubt advance our overall understanding of the mechanisms controlling the balance between immune effector and regulatory responses. Such knowledge will not only help advance potential specific treatments for autoimmune and allergic disorders, it will also have an impact on the development of ATVs for cancer and infectious disease.
Conclusions
APCs have a variety of receptors that mediate the sampling of antigens (both self and non-self) to integrate the innate with adaptive immune responses. In particular, CLRs are abundantly expressed on various APC populations and via the signal motifs in their cytoplasmic domains are able to route antigens to endosomal compartments that are important for antigen processing and presentation. However, most vaccination strategies still rely on the local uptake of antigen. The use of CLRspecific antibodies provides a novel way to exploit these pathways for induction of antigen-specific immunity using the beneficial properties of antibodies that can provide systemic delivery. In fact, preclinical models have demonstrated the efficacy of this strategy using a variety of experimental systems. From a development perspective, ATVs are a practical approach relative to some of the more personalized vaccine technologies. These products can be generated as fusion proteins containing an antigengenetically linked to the APC-binding human mAb. Therefore, the manufacturing, purification and characterization of these products are based on standardized procedures developed for mAbs, and consequently the regulatory requirements for such well-characterized products are understood. In contrast to traditional antibody approaches, antigens used in ATVs can be intracellular targets. These antigens may consist of either small diseasespecific peptides or entire proteins. Moreover, multiple antigens or epitopes defined from different antigens for inducing broader immune responses can be readily assembled into one construct.
Preclinical studies with ATVs have made it apparent that additional signals such as those afforded by adjuvants are likely to be important to elicit sustained immunity in humans (Figure 3) . Therefore, at least in this context, ATVs will need to be combined with agents that elicit complementary activation signals. Such signals may be provided by a number of immunostimulatory agents that are actively being investigated in the clinic, such as TLR agonists and cytokines. Although there has been less progress to date, the use of ATVs in the absence of activation signals, and perhaps with additional immune suppression, is an attractive opportunity for developing antigen-specific immune suppression.
Although the ATV technology has been in preclinical development for two decades, only recently has the first candidate molecule entered human clinical trials. Based on strong preclinical data with multiple approaches, additional ATV programs for oncology, infectious disease, and pathogens relevant to biodefense programs are likely to enter clinical development in the near future. In summary, antigen targeting to APCs using antibodies provides a specific and efficient antigen delivery platform for direct in vivo application. The addition of immune modulators to APC targeting is a critical feature of ATVs which may be required to tip the balance towards tolerance or immunity.
